Pharmaceutical company, AC Immune, announces a reduction in workforce by 30% and plans to concentrate its drug pipeline focus.
AC Immune, a Swiss biotech company specializing in the development of precision therapies for neurodegenerative indications, has announced a workforce reduction of 30% as part of an effort to extend its cash runway to Q3 2027.
Before the strategic initiatives, AC Immune's cash runway was enough to last until the first quarter of 2027. The layoffs aim to conserve resources and ensure the company's financial stability.
AC Immune is currently engaged in several partnerships with other pharmaceutical giants, including Johnson & Johnson's Janssen and Takeda. The partnership with Janssen focuses on the active immunotherapy ACI-35.030, an asset that generates antibodies against tau proteins in the context of Alzheimer's disease. The collaboration aims to advance the product in clinical development for preclinical Alzheimer's disease.
Similarly, AC Immune is collaborating with Takeda on the anti-amyloid-beta active immunotherapy ACI-24 for Alzheimer's disease. Interim data for this program is expected in the first half of 2026.
AC Immune's pipeline also includes assets developed independently, such as ACI-7104.056, an immunotherapy for Parkinson's disease currently in Phase II development. Data for this asset is expected before the end of the year.
The company's focus on neurodegenerative diseases extends to other pathways as well. AC Immune has three clinical-stage programs, each addressing the amyloid-beta, tau, and alpha-synuclein pathways. Two of these programs are in collaboration with Big Pharma partners.
In addition to these collaborations, AC Immune will also pursue its most promising small-molecule assets targeting tau proteins and the NLRP3 inflammasome.
As of June 30, 2025, AC Immune's cash balance was approximately 127.1 million Swiss Francs. However, the company reported a net loss of 21.2 million Swiss Francs in the second quarter of 2025.
AC Immune currently has 172 employees, a figure that is expected to decrease by 30% following the workforce reduction. The company's goal is to focus its pipeline and investments on its most important assets, ensuring a sustainable future in the challenging field of neurodegenerative disease research.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
